These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19025478)

  • 1. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.
    Chan-Tack KM; Struble KA; Birnkrant DB
    AIDS Patient Care STDS; 2008 Nov; 22(11):843-50. PubMed ID: 19025478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
    Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
    Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
    Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
    Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
    Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
    Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
    AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
    Mikl J; Sulkowski MS; Benhamou Y; Dieterich D; Pol S; Rockstroh J; Robinson PA; Ranga M; Stern JO
    BMC Infect Dis; 2009 Dec; 9():203. PubMed ID: 20003457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracranial hemorrhage with Aptivu.
    AIDS Patient Care STDS; 2006 Dec; 20(12):889. PubMed ID: 17216876
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
    Macías J; Orihuela F; Rivero A; Viciana P; Márquez M; Portilla J; Ríos MJ; Muñoz L; Pasquau J; Castaño MA; Abdel-Kader L; Pineda JA;
    J Antimicrob Chemother; 2009 Jan; 63(1):178-83. PubMed ID: 18952618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tipranavir: a new option for the treatment of drug-resistant HIV infection.
    Temesgen Z; Feinberg J
    Clin Infect Dis; 2007 Sep; 45(6):761-9. PubMed ID: 17712762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
    Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB
    AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
    Walmsley SL; Squires K; Weiss L; Easterbrook P; Orani A; Kraft M; Scherer J
    AIDS; 2009 Jan; 23(3):429-31. PubMed ID: 19114862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis.
    Chrysos G; Gerakari S; Stasini F; Kokkoris S; Kourousis D; Velegraki A
    J Infect; 2008 Jul; 57(1):85-7. PubMed ID: 18314196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?
    Justice AC; Zingmond DS; Gordon KS; Fultz SL; Goulet JL; King JT; Bravata DM; Valdez H; Kraft M; Mattocks KM;
    Clin Infect Dis; 2008 Nov; 47(9):1226-30. PubMed ID: 18831696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
    King JR; Acosta EP
    Clin Pharmacokinet; 2006; 45(7):665-82. PubMed ID: 16802849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.